These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 11076110

  • 1. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients.
    Collins AJ, St Peter WL, Dalleska FW, Ebben JP, Ma JZ.
    Clin Nephrol; 2000 Oct; 54(4):334-41. PubMed ID: 11076110
    [Abstract] [Full Text] [Related]

  • 2. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
    Sun PP, Perianayagam MC, Jaber BL.
    J Ren Nutr; 2009 Sep; 19(5):432-8. PubMed ID: 19464926
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 4. Sevelamer worsens metabolic acidosis in hemodialysis patients.
    De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, Di Stazio E, Stellato D, Santoro D, Di Meglio E, Iacono G, Ciacci C, Savica V, Cirillo M.
    J Nephrol; 2006 Jun; 19 Suppl 9():S108-14. PubMed ID: 16736432
    [Abstract] [Full Text] [Related]

  • 5. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage.
    Oka Y, Miyazaki M, Takatsu S, Kunitomo K, Uno F, Maruyama M, Matsuda H.
    Ther Apher Dial; 2007 Apr; 11(2):107-13. PubMed ID: 17381531
    [Abstract] [Full Text] [Related]

  • 6. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
    Suki WN, Dialysis Clinical Outcomes Revisited Investigators.
    J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R, Herman A, Ferreira C, Travassos F, Nunes-Azevedo J, Oliveira M.
    Nefrologia; 2002 Jan; 22(5):448-55. PubMed ID: 12497746
    [Abstract] [Full Text] [Related]

  • 9. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.
    Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, Chertow GM.
    Arthritis Rheum; 2005 Jan; 52(1):290-5. PubMed ID: 15641045
    [Abstract] [Full Text] [Related]

  • 10. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D.
    J Nephrol; 2001 Jan; 14(3):176-83. PubMed ID: 11439741
    [Abstract] [Full Text] [Related]

  • 11. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M.
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [Abstract] [Full Text] [Related]

  • 12. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, Kono T, Uchino J, Masaki K, Date T, Shigematsu T, Research Group for Future Hemodialysis.
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [Abstract] [Full Text] [Related]

  • 13. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
    Nolan CR.
    Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
    [Abstract] [Full Text] [Related]

  • 14. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
    Inoue T, Nagatoya K, Kagitani M, Shibahara N, Ueda H, Katsuoka Y, Ohashi S, Kitagawa Y, Nishimoto K, Yasuda H, Hokusetsu Renal Osteodystrophy Study Group.
    Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
    [Abstract] [Full Text] [Related]

  • 15. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
    Koiwa F, Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M, Shigematsu T, ROD 21 Clinical Research Group.
    Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
    Iwasaki Y, Takami H, Tani M, Yamaguchi Y, Goto H, Goto Y, Goto Y, Shigematsu T.
    Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
    [Abstract] [Full Text] [Related]

  • 17. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
    Sato M, Fukazawa S, Yasuda T, Akatsuka T, Tozawa S, Niida Y, Hashimoto N, Mochizuki T, Koike T.
    Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
    [Abstract] [Full Text] [Related]

  • 18. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.
    Nagano N, Miyata S, Obana S, Kobayashi N, Fukushima N, Burke SK, Wada M.
    Nephrol Dial Transplant; 2003 Oct; 18(10):2014-23. PubMed ID: 13679475
    [Abstract] [Full Text] [Related]

  • 19. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB, Shepler BM.
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [Abstract] [Full Text] [Related]

  • 20. Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results.
    St Peter WL, Liu J, Weinhandl ED, Fan Q.
    Hemodial Int; 2008 Oct; 12(4):480-91. PubMed ID: 19090871
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.